Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Focus: Lilly, Novo lock horns in India's obesity drug race
08:06pm, Tuesday, 23'rd Dec 2025
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
Final Trade: NVO, FCX, BA, CLF
06:25pm, Tuesday, 23'rd Dec 2025
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Launch of Wegovy pill is core to Novo Nordisk's growth, says Guggenheim's Seamus Fernandez
06:06pm, Tuesday, 23'rd Dec 2025
Guggenheim's Seamus Fernandez joins 'Fast Money' to talk Novo Nordisk getting Wegovy pill approved.
Market Today: GDP Jumps, S&P Record; Novo Nordisk (NVO) Pill OK
05:35pm, Tuesday, 23'rd Dec 2025
Guru Stock PicksThird Avenue Value Fund has made the following transactions:Reduce in XTER: BMW by 5.73%Sold out in XTER:MBGAdd in TSX: IFP by 56.31%New position
Stock Market Today, Dec. 23: U.S. Stocks Hold Near Records on Narrow Tech-Led Gains
05:21pm, Tuesday, 23'rd Dec 2025
Mega-cap tech and AI stocks carried major indexes in thin holiday trading, while healthcare strength after Novo Nordisk's Wegovy pill approval added selective support amid a resilient economic backdro
Why Novo Nordisk Stock Popped Today
05:03pm, Tuesday, 23'rd Dec 2025
Novo Nordisk's pill could be a convenient new option for adults seeking to lose weight. The worldwide market for weight-loss drugs could grow to a staggering $150 billion in the coming decade.
US health agency to expand access to GLP-1 weight-loss drugs
04:56pm, Tuesday, 23'rd Dec 2025
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss.
Dr. Ashish Jha talks Novo Nordisk getting approval for Wegovy pill
04:52pm, Tuesday, 23'rd Dec 2025
Dr. Ashish Jha, Brown School of Public Health, joins 'Closing Bell Overtime' to talk Novo Nordisk getting approval fro a Wegovy pill, sending its stock climbing.
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill
04:42pm, Tuesday, 23'rd Dec 2025
Expand NYSE: NVO Novo Nordisk Today's Change (7.30%) $3.51 Current Price $51.61 Key Data Points Market Cap $162B Day's Range $51.04 - $53.20 52wk Range $43.08 - $93.80 Volume 66M Avg Vol 16M Gross Mar
Major stock indexes rose for a fourth straight session Tuesday, with the S&P 500 poised to set a record-high close, after delayed third-quarter GDP data came in better than analysts expected.
Novo Nordisk is still worried about revenue growth next year despite obesity pill: BMO's Seigerman
03:04pm, Tuesday, 23'rd Dec 2025
Evan Seigerman, BMO head of healthcare research, joins 'Power Lunch' to discuss Seigerman's thoughts on Novo Nordisk, its competitor Eli Lilly and much more.
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus
02:04pm, Tuesday, 23'rd Dec 2025
The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to cho
Novo Nordisk stock: does oral Wegovy approval make it better pick than Eli Lilly?
01:42pm, Tuesday, 23'rd Dec 2025
HSBC's senior research analyst Rajesh Kumar believes Novo Nordisk (NYSE: NVO) “might have an edge” over rival Eli Lilly (NYSE: LLY) heading into 2026. His remarks arrive shortly after the Danish p
Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly's Looming Pill?
01:23pm, Tuesday, 23'rd Dec 2025
Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk ‘s ( NYSE:NVO ) Wegovy weight-loss pill, the first of its kind.
Novo Nordisk's Wegovy Pill Gains FDA Approval, Boosting Weight Loss Market Prospects
01:14pm, Tuesday, 23'rd Dec 2025
Novo Nordisk (NVO) saw a significant stock surge following the FDA's approval of the Wegovy pill for weight loss. This makes it the first oral GLP-1 receptor ag
